Reading SEPN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SEPN free→Reading SEPN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SEPN free→QuarterlyIQ Insights · SEPN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Other Events On March 1, 2026, the Company announced positive results from its Phase 1 clinical trial evaluating SEP-631, a potent and selective oral negative allosteric modulator (“NAM”) of Mas-related G protein-coupled receptor X2 (“MRGPRX2”), and outlined initial Phase 2 development strategy. Phase 1 Results SEP-631 was evaluated in a randomized, double-blind, placebo-controlled Phase 1 trial in healthy volunteers, including single-ascending dose, multiple-ascending dose and food-effect co…
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 25, 2025 (the “Appointment Date”), the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) expanded the size of the Board from seven to eight directors and appointed Keith Gottesdiener, M.D. to serve as a member of the Board and as a Class I director, to hold office for a three-year term expiring at the Company’s annual…
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 30, 2025, the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) appointed Liz Bhatt, M.S., M.B.A., the Company’s Chief Operating Officer, to serve as the Company’s President, in addition to continuing in her current role as Chief Operating Officer, effective as of August 1, 2025 (the “Effective Date”). Ms. Bhatt will assume…
Other Events. On July 1, 2025, the previously announced Collaboration and License Agreement, dated as of May 13, 2025 (the “Collaboration Agreement”), by and between Septerna, Inc. (the “Company”) and Novo Nordisk A/S, became effective following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. A summary of the terms of the Collaboration Agreement is set forth in the Company’s Current Report on Form 8-K filed with the Secur…
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Regulation FD Disclosure. On May 14, 2025, the Company issued a press release entitled “Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on the Form 8-K. In a separate business update, the Company now anticipates initiating a Phase 1 clinical trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics (through an icatibant sk…
Entry into a Material Definitive Agreement. On May 13, 2025, Septerna, Inc. (the “Company”) and Novo Nordisk A/S (“Novo”) entered into a global Collaboration and License Agreement (the “Collaboration Agreement”). Under the Collaboration Agreement, the Company and Novo will exclusively collaborate to leverage the Company’s proprietary Native Complex Platform ™ to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related disease s based on certai…
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.